

# Evaluation of lung ultrasound as a guiding tool for treatment adjustment in patients with heart failure admitted to hospital

<b>Submission date</b> 15/03/2022	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 21/03/2022	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 05/04/2023	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

Heart failure means that the heart is unable to pump blood around the body properly. It usually occurs because the heart has become too weak or stiff.

Lung congestion (a condition caused by excess fluid in the lungs) can be evaluated with lung ultrasound (a procedure that uses high-frequency sound waves to create an image of part of the inside of the body) in patients with heart failure.

The aim of this study is to evaluate if lung ultrasound may guide heart failure treatment improving clinical outcomes (survival or the need of intravenous diuretics).

### Who can participate?

Adult patients with heart failure.

### What does the study involve?

Participants will receive heart failure treatment (above all diuretic treatment) guided by lung ultrasound lung congestion results or following standard of care management using physical examination. Clinical outcomes will be registered during 6 months.

### What are the possible benefits and risks of participating?

The benefit is to obtain better outcomes like less mortality or less readmission rate. Risks are related to an excess of diuretic doses that may generate hypotension or renal failure.

### Where is the study run from?

Sociedad Española de Medicina Interna (Spain)

### When is the study starting and how long is it expected to run for?

September 2017 to March 2021

### Who is funding the study?

Investigator initiated and funded

Who is the main contact?

Dr Juan Torres-Macho, [juan.torresm@salud.madrid.org](mailto:juan.torresm@salud.madrid.org)

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Juan Torres-Macho

### ORCID ID

<https://orcid.org/0000-0002-8860-6837>

### Contact details

C/ Gran Vía del Este, 80

Madrid

Spain

28031

+34 9119138000

[juan.torresm@salud.madrid.org](mailto:juan.torresm@salud.madrid.org)

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

Nil known

## Study information

### Scientific Title

Effect of a therapeutic strategy guided by lung ultrasound on 6-month outcomes in patients with heart failure. The EPICC trial

### Acronym

EPICC

### Study objectives

Pulmonary congestion (PC) is associated with an increased risk of hospitalization and death in patients with heart failure (HF). Lung ultrasound has shown to be highly sensitive for detecting PC in HF. The aim of this study is to evaluate whether lung ultrasound-guided therapy improves 6-month outcomes in patients with HF compared with conventional treatment.

### Ethics approval required

Old ethics approval format

### **Ethics approval(s)**

Approved 25/02/2019, CEIm Hospital Universitario Puerta de Hierro (C/ Joaquín Rodrigo, 2. 28222 Majadahonda, Madrid, Spain; +34 91 191 60 00; no email provided), ref: 28981

### **Study design**

Interventional randomized controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Diagnostic

### **Health condition(s) or problem(s) studied**

Heart failure

### **Interventions**

Randomized, multicenter, single-blind clinical trial in patients discharged from Internal Medicine Departments after hospitalization for decompensated HF. Randomization was performed via an online tool.

Participants were assigned 1:1 to receive treatment guided according to the presence of lung ultrasound signs of congestion (semi-quantitative evaluation of B lines and the presence of pleural effusion) versus clinical assessment of congestion (standard of care).

Participants were followed up for 6 months.

### **Intervention Type**

Other

### **Primary outcome(s)**

Cardiovascular death, admission due to heart failure, emergency department visit due to heart failure, diuretic administration at day hospital measured using patient records at 6 months

### **Key secondary outcome(s)**

There are no secondary outcome measures

### **Completion date**

01/03/2021

## **Eligibility**

### **Key inclusion criteria**

1. Age older than 18 y
2. NYHA functional class  $\geq$ II at inclusion
3. Able to attend ambulatory follow-up visits

### **Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Sex**

All

**Total final enrolment**

79

**Key exclusion criteria**

1. Life expectancy <6 months due to a different medical condition than HF
2. Heart transplantation
3. Acute coronary syndrome
4. Recent coronary revascularization
5. Valve replacement or resynchronization in the prior 3 months
6. Pregnancy
7. Restrictive pulmonary disease or severe COPD needing continuous oxygen
8. Serum creatinine >3 mg/dl or chronic renal insufficiency in dialysis
9. Severe valve stenosis
10. Participation in another randomized study

**Date of first enrolment**

01/09/2018

**Date of final enrolment**

01/09/2020

**Locations****Countries of recruitment**

Spain

**Study participating centre**

Hospital Universitario Infanta Cristina

Parla

Spain

28981

**Study participating centre**

Hospital Universitario Clinico San Carlos

Madrid

Spain  
28040

**Study participating centre**

**Hospital de Zafra**

Zafra  
Spain  
06300

**Study participating centre**

**Hospital Vega Baja**

Orihuela  
Spain  
03314

**Study participating centre**

**Hospital Universitario Ramón y Cajal**

Madrid  
Spain  
28034

**Study participating centre**

**Hospital Lucus Augusti**

Lugo  
Spain  
27003

## **Sponsor information**

**Organisation**

Sociedad Española de Medicina Interna

**ROR**

<https://ror.org/0031gef94>

## **Funder(s)**

## Funder type

Other

## Funder Name

Investigator initiated and funded

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated and/or analysed during the current study will be published as a supplement to the publication of the subsequent results

## IPD sharing plan summary

Published as a supplement to the results publication

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	22/08/2022	05/04/2023	Yes	No
<a href="#">Protocol article</a>		22/07/2019	18/03/2022	Yes	No